MSC Cruises S.A., the world’s largest privately-owned global cruise line and market leader in Europe – including in the Mediterranean – and in South America announced today plans for enhancing its already rich beauty and care offer available to guests on its fleet, by adding targeted winkle treatments with Botulinum and dermal fillertreatments with hyaluronic acid, the Company said in a press release.
Guests on the 12 ships of the MSC Cruises fleet will now have the opportunity to indulge on a range of targeted wrinkle and dermal filler treatments in a completely secure environment with doctors who have received specialised and exhaustive training, another way for the Company to distinguish itself in the best-in-class experience it provides its guests during their holidays.
MSC Cruises is an ambitious young line that grew 800% in its first 10 years to become the fourth largest cruise company in the industry. The Company is set to double its fleet capacity by 2022, through a €5.1 billion investment plan, which includes orders for seven ships in two state-of-the-art prototypes.
Of these ships, MSC Cruises recently also announced the opening of sales for MSC Meraviglia’s inaugural cruises – the Company’s first new-generation ship, which is part of the above-mentioned investment plan. As of June 2017, the ship will sail in the Mediterranean from Barcelona, Genoa or Marseille. The second next-generation ship currently under construction, MSC Seaside will on the other hand sail year-round in the Caribbean starting in December 2017.
All news